Galapagos ( ($GLPG) ) just unveiled an update. On November 3, 2025, Galapagos NV announced that it will present new data for its CAR T-cell ...
Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the ...
GlobalData on MSN
IntoCell and Xcellon Biologics to advance ADC development
Xcellon Biologics will incorporate IntoCell’s OHPAS drug-linker system into its range of ADC development suites.
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an ...
13don MSN
Decoding the T cell burst: Signature genes predict T cell expansion in cancer immunotherapy
The ability of immune cells—particularly CD8+ T cells—to launch a rapid burst of proliferation inside tumors is key to the ...
The FDA has released three new guidance documents on cell and gene therapy development, covering clinical trial design and ...
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in ...
Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell ...
7d
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with ...
News-Medical.Net on MSN
Researchers develop a novel approach to monitor CD8⁺ T cell activity over time
The ability of immune cells-particularly CD8+ T cells-to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback